Silver Scott Mines Explores Institutional-Grade Blockchain Assets for Treasury Reserves
The Company has initiated evaluation of the regulatory framework surrounding a strategic asset acquisition program focused on selected digital assets to strengthen treasury reserves for application development and enhance long-term shareholder value. Ondo Finance (ONDO) has established itself as a market leader in the RWA tokenization sector with its comprehensive compliance infrastructure and institutional-grade protocols for bringing traditional financial assets onto the blockchain ecosystem. Ondo's regulatory-first methodology aligns strategically with Silver Scott's commitment to compliant RWA tokenization practices.
The company is also evaluating Pax Gold (PAXG), a gold-backed token where each token represents one fine troy ounce of gold. This strategic move connects directly with Silver Scott's core business of tokenizing gold mining assets while providing stability during uncertain geopolitical times.
This strategic initiative represents Silver Scott's disciplined approach to treasury management with digital assets, maintaining allocations below thresholds stipulated in the Investment Company Act of 1940, while enhancing its business model in volatile market conditions. The Company maintains its commitment to creating shareholder value through innovative blockchain solutions backed by real-world assets. To learn more about our asset tokenization service visit https://silverscottdigital.com/tokenization/
About Silver Scott Mines, Inc
Silver Scott Mines, Inc. (OTC:SILS) is a forward-focused holding company accelerating blockchain integration across traditional asset classes. Specializing in private blockchain solutions for institutional-grade tokenization, the company enables fractional ownership models and cryptographic validation of assets through TrustNFT technology. The company acquisition pipeline will target blockchain-enhanced opportunities in healthcare, cleantech, and digital platforms. https://www.silverscottdigital.com LinkedIn: www.linkedin.com/company/silverscott-blockchain X: https://x.com/silverscottmine
Forward Looking Statements This press release includes forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. Words such as expects, believes, anticipates, intends, estimates, seeks and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Silver Scott Mines, are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements.
Stuart Fine
CEO
908-356-9852
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
First Solar, Inc. (FSLR): A Bull Case Theory
We came across a bullish thesis on First Solar, Inc. on Stock Analysis Compilation's Substack. In this article, we will summarize the bulls' thesis on FSLR. First Solar, Inc.'s share was trading at $180.72 as of July 24th. FSLR's trailing and forward P/E were 15.27 and 11.86, respectively according to Yahoo Finance. A photovoltaic field at dawn, its solar panels shimmering in the light of a new day. First Solar, Inc. (FSLR), a U.S.-based photovoltaic solar technology and manufacturing company, is uniquely positioned to capitalize on the rising energy demands driven by AI infrastructure growth and supportive 'America First' energy policies. As the only U.S. solar module manufacturer operating at scale, FSLR benefits from structural tailwinds favoring domestic production, with its sales already fully booked through 2026. Demand momentum is expected to build further as developers rush to secure capacity that qualifies for subsidies ahead of the expiration of key provisions under the Inflation Reduction Act (IRA). Clarity on final IRA rules is anticipated to accelerate contract wins, providing additional visibility and backlog security. FSLR's positioning as the go-to domestic supplier, coupled with its technological expertise, makes it a prime beneficiary of policy-driven reshoring and the surge in utility-scale solar projects catering to the rapidly expanding AI data center ecosystem. This demand pull-through is underpinned by the urgent need to meet soaring energy consumption with renewable generation, reinforcing FSLR's long-term growth trajectory. The company's solid backlog, strong policy support, and strategic market leadership offer investors a high degree of revenue certainty, with upside potential as further contracts are secured under favorable subsidy terms. As AI-driven electricity consumption accelerates, FSLR's unique scale and subsidy-qualified pipeline position it to capture outsized market share, offering an attractive risk/reward profile. Together, these dynamics create a compelling investment case supported by structural growth, policy-driven advantages, and near-term catalysts that enhance earnings visibility and reinforce the company's strategic importance in the U.S. energy transition. Previously, we covered a on First Solar, Inc. (FSLR) by Oliver | MMMT Wealth in April 2025, which highlighted FSLR's CdTe technology, insulation from Chinese supply chains, and benefits from U.S. protectionist trade policies. The company's stock price has appreciated by approximately 39% since our coverage. This is because the thesis played out with policy support and demand tailwinds. Stock Analysis Compilation shares a similar view but emphasizes AI-driven energy demand and IRA subsidies as key growth catalysts. First Solar, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held FSLR at the end of the first quarter which was 65 in the previous quarter. While we acknowledge the potential of FSLR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Business Wire
2 hours ago
- Business Wire
TC BANCSHARES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TC Bancshares, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of TC Bancshares, Inc. (OTC: TCBC) to Colony Bankcorp, Inc. (NYSE: CBAN). Under the terms of the proposed transaction, shareholders of TC will have the right to elect to receive either $21.25 in cash or 1.25 shares of Colony's common stock in exchange for each share of TC Bancshares common stock, subject to customary proration and allocation procedures such that approximately 20% of TC Bancshares common stock will be converted to cash consideration and the remaining 80% will be converted to Colony common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Hamilton Spectator
3 hours ago
- Hamilton Spectator
PharmAla Issues Q3 Financial Statements
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ('PharmAla' or the 'Company') (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company's full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management's discussion and analysis can be accessed by visiting the Company's website at and its profile page on SEDAR+ at . 'The re-opening of PharmAla's domestic Canadian distribution has allowed us to execute as much volume in Q2 and Q3 as we did in all of the last fiscal year. The creation of our Prescriber's Portal has also allowed us to build a much closer relationship with our doctor customers, which we believe will serve us well moving forward,' said Nick Kadysh, CEO, PharmAla Biotech. 'As we move into the last quarter of Fiscal '24-25, we are incredibly pleased that a large shipment of LaNeo MDMA has arrived at our US distribution partner for delivery to a considerable group of clinical trial customers, most previously announced. PharmAla is also pleased to announce the completion of a manufacturing run in Australia for our 40mg LaNeo Capsules. These capsules were jointly manufactured for both Cortexa's use within Australia and PharmAla's use worldwide, and our improved manufacturing process should yield operational benefits well into the future.' Financial Highlights: 'Over the past quarter, our team has made exciting progress to ensure a reliable supply of pharmaceutical product for both researchers in clinical trials and patients in need of treatment,' said Will Avery, CFO, PharmAla Biotech. 'Our Prescriber Platform continues to empower physicians to access the MDMA and provide treatment for their patients and we look forward to additional clinical trial fulfillment to US and international customers in the near term, unburdened by cross-border trade issues.' About PharmAla PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a 'regulatory first' organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. For more information, please contact: Nicholas Kadysh Chief Executive Officer PharmAla Biotech Holdings Inc. Email: press@ Phone: 1-855-444-6362 Website: Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'strategy', 'expects' or 'does not expect', 'intends', 'continues', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or may contain statements that certain actions, events or results 'will be taken', 'will launch' or 'will be launching', 'will include', 'will allow', 'will be made' 'will continue', 'will occur' or 'will be achieved'. We direct readers to refer to the 'Caution Regarding Forward-Looking Statements' contained within the Company's management's discussion and analysis for the period ended May 31, 2025, as filed on Sedar+ . Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed in the Company's management's discussion and analysis, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at , which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
